Tenax Therapeutics Files 8-K Report
Ticker: TENX · Form: 8-K · Filed: Dec 17, 2025 · CIK: 34956
| Field | Detail |
|---|---|
| Company | Tenax Therapeutics, INC. (TENX) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, corporate-update
Related Tickers: TENX
TL;DR
TENX filed an 8-K on 12/17/25, likely containing important company updates.
AI Summary
On December 17, 2025, Tenax Therapeutics, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences. No specific financial figures or new events were detailed in the provided excerpt.
Why It Matters
This filing signals that Tenax Therapeutics is providing updated information to the SEC, which could include material events or financial disclosures relevant to investors.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report without immediate negative or positive financial implications detailed in the excerpt.
Key Players & Entities
- TENAX THERAPEUTICS, INC. (company) — Registrant
- December 17, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-34600 (commission_file_number) — SEC File Number
- 26-2593535 (ein) — IRS Employer Identification No.
- 101 Glen Lennox Drive , Suite 300 Chapel Hill , NC 27517 (address) — Business Address
FAQ
What is the primary purpose of this 8-K filing by Tenax Therapeutics?
The filing is for "Other Events" and "Financial Statements and Exhibits," indicating updates or disclosures related to the company's financial status and significant occurrences.
On what date was this 8-K report filed or effective?
The report's earliest event date is December 17, 2025.
What is Tenax Therapeutics' state of incorporation?
Tenax Therapeutics, Inc. is incorporated in Delaware.
What is the SEC file number for Tenax Therapeutics?
The SEC file number for Tenax Therapeutics is 001-34600.
What is the business address of Tenax Therapeutics?
The business address is 101 Glen Lennox Drive, Suite 300, Chapel Hill, NC 27517.
Filing Stats: 515 words · 2 min read · ~2 pages · Grade level 11.1 · Accepted 2025-12-17 17:00:18
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share TENX The Nasdaq
Filing Documents
- tennx_8k.htm (8-K) — 24KB
- tennx_ex991.htm (EX-99.1) — 13KB
- tennx_ex991img1.jpg (GRAPHIC) — 3KB
- tennx_ex991img2.jpg (GRAPHIC) — 3KB
- 0001654954-25-014059.txt ( ) — 163KB
- tennx-20251217.xsd (EX-101.SCH) — 5KB
- tennx-20251217_lab.xml (EX-101.LAB) — 14KB
- tennx-20251217_cal.xml (EX-101.CAL) — 1KB
- tennx-20251217_pre.xml (EX-101.PRE) — 9KB
- tennx-20251217_def.xml (EX-101.DEF) — 2KB
- tennx_8k_htm.xml (XML) — 4KB
01 Other Events
Item 8.01 Other Events. On December 17, 2025, Tenax Therapeutics, Inc. (the "Company") issued a press release announcing that the prespecified Blinded Sample Size Re-estimation (BSSR) of LEVEL, an ongoing, registrational Phase 3 clinical trial evaluating TNX-103 (oral levosimendan) in patients with pulmonary hypertension in heart failure with preserved ejection fraction (PH-HFpEF) in the United States and Canada, demonstrated the trial is powered at well over 90% to detect a 25 meter change in 6-minute walk distance (6MWD), the primary endpoint. Based on these results, Tenax confirmed the previously announced target enrollment number and expected enrollment completion timeframe as well as topline data timeframe. The Company also announced that it has initiated its global Phase 3 LEVEL-2 study, the second registrational Phase 3 study of TNX-103 in patients with PH-HFpEF. A copy of the press release is attached hereto as Exhibit 99.1.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release dated December 17, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 17, 2025 Tenax Therapeutics, Inc. By: /s/ Christopher T. Giordano Christopher T. Giordano President and Chief Executive Officer 3